Current advances in HIV vaccine preclinical studies using Macaque models

Area of Science:

• Immunology
• Vaccinology
• Primate Models

Background:

• The simian or simian/human immunodeficiency virus (SIV/SHIV) macaque model is crucial for human immunodeficiency virus (HIV) vaccine development.
• Recent advancements include the repeated-low-dose (RLD) challenge approach to assess vaccine efficacy (VE).

Purpose of the Study:

• To review key parameters within the RLD approach for SIV/SHIV challenge studies.
• To discuss the relevance of these parameters in evaluating vaccine efficacy.
• To improve the predictive value of preclinical studies for candidate HIV vaccines.

Main Methods:

• Literature review of SIV/SHIV challenge studies utilizing the RLD approach.
• Analysis of critical parameters influencing vaccine efficacy assessment in macaques.
• Discussion of the translational relevance of macaque model findings to human vaccine trials.

Main Results:

• The RLD approach offers a refined method for assessing SIV/SHIV vaccine efficacy in preclinical settings.
• Specific parameters within the RLD model significantly impact the interpretation of vaccine-induced protection.
• Candidate HIV vaccines have demonstrated protective effects in macaque models, warranting further investigation.

Conclusions:

• Optimizing parameters in the SIV/SHIV RLD macaque model is essential for robust preclinical vaccine evaluation.
• Further validation is needed to confirm the predictive value of this model for human HIV vaccine efficacy.
• Improved preclinical assessment through refined RLD methodologies can accelerate the development of effective HIV vaccines.